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Abstract
Background: Standard biological parts, such as BioBricks™ parts, provide the foundation for a new engineering
discipline that enables the design and construction of synthetic biological systems with a variety of applications in
bioenergy, new materials, therapeutics, and environmental remediation. Although the original BioBricks™ assembly
standard has found widespread use, it has several shortcomings that limit its range of potential applications. In
particular, the system is not suitable for the construction of protein fusions due to an unfavorable scar sequence
that encodes an in-frame stop codon.
Results: Here, we present a similar but new composition standard, called BglBricks, that addresses the scar
translation issue associated with the original standard. The new system employs BglII and BamHI restriction
enzymes, robust cutters with an extensive history of use, and results in a 6-nucleotide scar sequence encoding
glycine-serine, an innocuous peptide linker in most protein fusion applications. We demonstrate the utility of the
new standard in three distinct applications, including the construction of constitutively active gene expression
devices with a wide range of expression profiles, the construction of chimeric, multi-domain protein fusions, and
the targeted integration of functional DNA sequences into specific loci of the E. coli genome.
Conclusions: The BglBrick standard provides a new, more flexible platform from which to generate standard
biological parts and automate DNA assembly. Work on BglBrick assembly reactions, as well as on the development
of automation and bioinformatics tools, is currently underway. These tools will provide a foundation from which to
transform genetic engineering from a technically intensive art into a purely design-based discipline.
Background
Synthetic biology takes a ground-up approach to geneti-
cally engineer cellular systems capable of the sophisti-
cated sensing, information processing, and actuation
exhibited by natural systems. While it is important to
build increasingly complex systems when necessary, the
goal is to do so using tools and methodologies that
streamline biology and make it easier to engineer. At
the center of this approach lies the need to impart novel
biological function(s) by systematically introducing new
designed DNA sequences into living cells. The two main
challenges in this endeavor are: first, knowing how to
design sequences that impart a particular function; and
second, how to construct the DNA encoding such func-
tion in a form that can be readily introduced into the
cell. Standard assembly parts, such as BioBricks™ [1],
provide a paradigm that addresses both of these pro-
blems by recognizing that functional units of DNA
sequence are frequently reused in a variety of projects.
These units, which include promoters, ribosome binding
sites, protein coding sequences, among others, represent
non-reducible elements of genetic composition, and as
such, are considered “basic parts.” The sequences of
each part are stored within databases, such as the Regis-
try of Standard Biological Parts [2], while the physical
DNAs are housed in part collections. Each basic part is
a genetic element that has been refined to comply with
any of several publicly-available standards and is not
associated with one particular assembly strategy. Never-
theless, because each part is standardized to conform to
a defined set of rules, a single standard assembly reac-
tion can be used to concatenate basic parts. Further-
more, because only one standard assembly reaction is
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assemble multi-part devices and characterize the rules
of functional composition for each part in the context
of other parts [3,4]. Thus, by standardizing the basic
part junction sequence, the task of defining contextual
rules for part function is significantly narrowed. We
envision that a robust standardized assembly process
will enable the development of low-cost, high-through-
put, automated assembly facilities, and ultimately, the
outsourcing of entire DNA fabrication processes at a
reasonable price.
The BioBricks™ s t a n d a r dd e s c r i b e db yK n i g h ta n d
coworkers was the first implementation of a strategy for
defining composition rules that allow the assembly of
standard biological parts using a single assembly chem-
istry [1]. The assembly method employs iterative restric-
tion enzyme digestion and ligation reactions to assemble
small basic parts into larger composite parts. Basic parts
are flanked by XbaI and SpeI restriction sites on their 5’
and 3’ ends, respectively. Digestion with these enzymes
generates compatible cohesive ends that can be ligated
back together head-to-tail. The ligation of two parts
generates a scar sequence between the parts that con-
tains neither of the original sites, and thus, it is unaf-
fected by subsequent digestion with either XbaI or SpeI.
The resulting product is a new composite part with the
same assembly characteristics as the two parent parts. It
is still flanked by unique XbaI and SpeI restriction sites
on its 5’ and 3’ ends, respectively, and hence, the itera-
tive assembly of larger and larger composite parts
becomes possible. Over 2,000 basic parts that conform
to this standard have been described, and they have
been used in the construction of a wide range of genetic
circuits and biosynthetic devices [5-8].
Since the inception of the first assembly standard, sev-
eral others have been proposed and/or developed to
describe functional composition and/or physical assem-
bly. In fact, this field is currently undergoing robust
activity, and the number of assembly standards is
expanding rapidly. At present, the BioBricks Foundation
(BBF) has implemented an organizational framework,
known as a BBF RFC (request for comments) process,
to help define, evaluate, and propose new standards in
the field [9]. As an example, we refer the reader to BBF
RFC 29 which describes the major assembly standards
proposed to date and suggests an organized naming pro-
cess for future standards [10]. One issue with the origi-
nal BioBricks™ standard, and addressed herein, is the
ability to compose protein-fusion parts encoding ele-
ments such as peptide tags and single domains of poly-
peptides for protein engineering applications.
Modular protein engineering is an emerging area of
synthetic biology. Several studies have shown the power
of building sophisticated protein machines by
assembling multiple modular domains into a variety of
larger polypeptide sequences [6,11-14]. Unfortunately,
the original BioBricks™ assembly scheme (BBF RFC 10)
is not suitable for building chimeric proteins because
t h e8 - n u c l e o t i d es c a rs e q u e n c et h a tr e m a i n sb e t w e e n
parts after they have been joined together is incompati-
ble with protein fusions for two reasons: first, the scar
sequence (TACTAGAG) encodes tyrosine followed by a
stop codon; and second, an 8 nucleotide scar inserts a
frame shift between the two coding sequences. Theoreti-
cally, this problem could be addressed by elongating the
scar sequence to contain a number of nucleotides that is
a multiple of 3, such that the stop codon is no longer in
frame and the frame shift is eliminated. In the mean
time, a number of improvements to the original Bio-
Bricks™ standard, along with completely alternative
assembly strategies and standards, have been proposed
and/or developed. The Biofusion standard (BBF RFC
23), for example, modifies the original BioBricks™ stan-
dard to create a smaller, 6 nucleotide scar sequence
(ACTAGA) that encodes threonine-arginine, and thus,
eliminates both reading frame shifts and encoded stop
codons [15]. Unfortunately, the AGA codon encoding
arginine is a rare codon in E. coli, and furthermore, the
XbaI site can be blocked by dam methylation when
flanked by certain sequences [15]. The Fusion Parts
standard (BBF RFC 25), developed by the Freiburg 2007
iGEM team, is another extension of the BioBricks™ stan-
dard that seeks to alleviate some of the disadvantages of
the Biofusion format. Here, AgeI and NgoMIV restric-
tion sites are used to generate a 6 nucleotide scar
sequence (ACCGGC) encoding threonine-glycine.
Finally, the BioBricks++ standard is a scarless assembly
standard that uses two steps for assembly [16]. It uses
type IIs restriction enzymes to recognize sites flanking
the part and digest at the boundary of the part. The
cohesive ends are then blunted prior to scarless ligation,
which is the ultimate goal of standard assembly strate-
gies. Unfortunately, robust reactions necessary to imple-
ment such a method have yet to be identified. All of
these standards, along with a complete list of their
advantages and disadvantages, are described further at
the BBF’s Standards and Formats page [17].
Here we describe a new robust, yet flexible, standard
for composing biological parts called BglBricks [18]. The
new standard addresses several of the key problems
associated with the original BioBricks™ standard, and
furthermore, it provides a foundation for developing
automated assembly platforms. The BglBrick standard
supports assembly with the BglII and BamHI restriction
enzymes flanking the 5’ and 3’ ends of basic parts,
respectively. These enzymes possess several advantages
over the ones used in previous standards: first, they
have an extensive history of use, which ensures their
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they are unaffected by overlapping dam or dcm methy-
lation; finally, they result in a 6-nucleotide scar sequence
(GGATCT) encoding glycine-serine, a sequence demon-
strated to be innocuous in most protein fusion applica-
tions in a variety of host systems, including E. coli,
yeast, and humans [19-21]. In the following sections, we
showcase uses of the BglBrick standard in 3 diverse
applications. These include the construction of constitu-
tively active gene expression devices that elicit a wide
range of expression profiles; the construction of chi-
meric, multi-domain fusion protein expression devices;
and finally, the targeted integration of parts and devices
into specific loci of the E. coli genome.
Results
Definition of the BglBrick standard
At its core, the BglBrick standard is a composition stan-
dard that enables idempotent assembly schemes using
BglII and BamHI restriction enzymes for assembly of
biological parts. As defined herein, the BglBrick standard
deals with the theoretical composition of DNAs, but not
their physical assembly. While it is designed as a mini-
m a ls t a n d a r dt h a te n a b l e sv ector and part compatibility
and the precise description of the products of restriction
enzyme-based manipulations, it imposes no further
explicit rules on composition. Here, only the rules
needed to support part and vector description, intercon-
version with EcoRI and BamHI, and concatenation with
XhoI, BamHI, and BglII are formally defined (Table 1).
Thus, the omission of extensive assembly details is
intentional given that BglBrick parts can be assembled
using a variety of different methods, including PCR-
based assembly. A BglBrick part is defined as a DNA
sequence flanked by “GATCT” on the 5’ end and by “G”
on the 3’ end, and lacking internal BamHI, BglII, EcoRI,
and XhoI restriction sites. A BglBrick vector is defined
as a DNA sequence flanked by “GATCC” on its 5’ end
and by “A” on its 3’ end. A BglBrick plasmid is defined
as a BglBrick vector plus a BglBrick part, where the part
can be either basic or composite. The nomenclature for
a BglBrick plasmid is “vectorName-partName,” and its
sequence is the concatenation of its vector and part(s)
sequences. Each vector or part sequence carries a
unique name corresponding to its exact sequence. Deri-
vatives of a BglBrick vector or part differing by even a
single nucleotide carry a unique name. Most (but not
all) BglBrick plasmids encode an EcoRI-BglII-BglBrick
part-BamHI-XhoI cassette. A BglBrick entry vector is a
special type of vector used to harbor basic parts and
support their assembly, and is defined as a sequence
containing a unique EcoRI site, no BamHI or BglII sites,
a n da tm o s to n eX h o Is i t e5 ’ to the EcoRI site. The
EcoRI site is used to facilitate part transfers between
different vectors. It can also be used for “prefix” inser-
tion assembly reactions (the prefix region is the vector
fragment between EcoRI and BglII). Similarly, if present,
the XhoI site can be used to facilitate “suffix” insertion
assembly reactions (the suffix region is the vector frag-
ment between BamHI and XhoI). Given the core defini-
tion of the BglBrick standard as a minimal assembly
standard that guarantees compatibility but imposes no
explicit rules on composition, start and stop codons are
n o tp a r to ft h ed e f i n i t i o n .S i m ilarly, the core definition
places no constraints on the location of other restriction
sites, origins of replication, and antibiotic selection mar-
kers, or on the length and sequence of the “prefix” and
“suffix” regions. Such further constraints, considered
sub-standards of the BglBrick format, are dynamic com-
munity-defined rules collected and described by the BBF
RFC process [9]. These sub-standards may include rules
for the location of the start codon of a coding sequence,
locations of other restriction sites, vector sets for speci-
fic standard assembly protocols, etc.
Standard assembly
Prefix insertion is one strategy for standard assembly of
BglBrick parts facilitated by plasmids containing a
BglBrick entry vector. Such plasmids encode unique
BglII and BamHI restriction sites flanking the 5’ and 3’
ends, respectively, of the parts to be joined (Figure 1).
Briefly, to join two basic parts A and B, in that order,
plasmid containing part A is digested with BamHI
(which cuts 3’ of the part) and EcoRI (which cuts the
vector), while plasmid containing part B is digested with
BglII (which cuts 5’ of the part) and EcoRI. The two
basic parts are connected head-to-tail by ligation to gen-
erate a composite part, which itself is flanked by unique
BglII and BamHI sites on its 5’ and 3’ ends, respectively.
Within the new composite part, parts A and B are sepa-
rated by a 6-nucleotide scar sequence. When translated
in frame, the scar sequence encodes glycine-serine, an
innocuous peptide linker for protein fusions. To date,
over 1,000 distinct BglBrick plasmids have been con-
structed. In the following sections, we showcase use of
Table 1 Core definitions of the BglBrick standard
BglBrick
plasmid
A BglBrick vector plus a BglBrick part, where the part
can be either basic or composite. The nomenclature
for a BglBrick plasmid is “vectorName-partName” and
its sequence is the concatenation of its vector and
part(s) sequences.
BglBrick part A DNA sequence flanked by “GATCT” on the 5’ end
and by “G” on the 3’ end, and lacking BamHI, BglII,
EcoRI, and XhoI restriction sites.
BglBrick vector A DNA sequence flanked by “GATCC” on its 5’ end
and by “A” on its 3’ end.
BglBrick entry
vector
A special type of vector sequence containing a
unique EcoRI site, no BamHI or BglII restriction sites,
and at most one XhoI site 5’ to the EcoRI site.
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construction of constitutively active gene expression
devices that elicit a wide range of expression profiles;
the targeted integration of parts and devices into specific
loci of the E. coli genome; and the construction of chi-
meric, multi-domain protein expression devices.
Assembly of protein expression devices with ranging
expression profiles
One of the recurring goals of synthetic biology is to pre-
dictably and reliably identify DNA sequences that confer
a specific biological property at a precise level of activity.
A generalized approach to this goal is to encapsulate
quantitative information about the function of specific
parts. To begin to address this, we tested a library of
ribosome binding sites (RBSs) for their ability to confer
varied levels of translation efficiency in the context of
the BglBrick format (Figure 2). We first created a library
of RBS parts in a BglBrick plasmid by saturation muta-
genesis. Of the mutants obtained, we selected several
variants that spanned the range of RBS activities
observed within the library for use as basic parts. Using
standard assembly, we constructed a series of composite
parts consisting of a constitutively active Tet promoter,
one RBS variant, and a lacZ coding sequence. The b-
galactosidase activity of each variant was determined by
Miller assay and showed a 100-fold range of activity
over the conditions tested. These experiments demon-
strate that BglBrick assem b l yc a nb eu s e dt oc r e a t ea
series of functional protein expression devices exhibiting
a wide variety of expression profiles.
Assembly of multi-domain fusion protein devices
One of the main advantages of the BglBrick standard is
that the 6 nucleotide scar produced after assembly of
two adjacent parts encodes a glycine-serine flexible lin-
ker when translated in-frame. To demonstrate that the
BglBrick standard can be used to assemble functional
fusion protein devices composed of several ORF parts,
we constructed devices encoding multiple domains,
including several repeats of protein-protein interaction
motifs. The devices were engineered to encode “bait”
proteins, and tested for their ability to pull down “prey”
using in-vitro pull down assays. To make the bait
devices, we first assembled composite parts containing
either 0, 1, or 4 repeats of an SH3 interaction motif
containing an N-terminal glycine-serine linker that were
separated by the BglBrick scar sequence, which added
an additional glycine-serine repeat. We also used the
BglBrick standard to tether these composite parts to the
C-terminus of the enzyme HMG-CoA synthase
(HMGS). Additionally, HMGS was N-terminally tagged
with GST to aid in protein purification. As prey, we
used HMG CoA reductase (HMGR), N-terminally
t a g g e dw i t ha nS H 3i n t e r a c t i o nd o m a i n[ 6 ] .I nt h e s e
experiments, HMGS and HMGR were used as “carriers”
of the bait SH3 peptide ligand repeat and the prey SH3
domain, and thus, should be considered inert for the
desired binding function.
Restriction enzyme-based assembly is a particularly
attractive strategy for the construction of devices with
repetitive elements, which can be problematic for two
main reasons. First, devices containing repetitive
sequences are difficult to create using PCR-based meth-
ods because misaligning and erroneous annealing of pri-
mers often produces shorter than desired products.
Second, sequences containing repetitive elements can be
targets for recombination, which can often lead to
   EcoRI    BglII           BamHI    XhoI
5’-GAATTCatgAGATCT <part 1> GGATCCtaaCTCGAG-3’
3’-CTTAAGtacTCTAGA <part 1> CCTAGGattGAGCTC-5’
5’-GAATTCatgAGATCT <part 2> GGATCCtaaCTCGAG-3’
3’-CTTAAGtacTCTAGA <part 2> CCTAGGattGAGCTC-5’
                             Scar
5’-GAATTCatgAGATCT <part 1> GGATCT <part 2> GGATCCtaaCTCGAG-3’
3’-CTTAAGtacTCTAGA <part 1> CCTAGA <part 2> CCTAGGattGAGCTC-5’
                            GlySer
Figure 1 Standard assembly of BglBrick parts. Unique BglII (in red) and BamHI (in blue) restriction sites flank BglBrick basic parts on their 5’
and 3’ ends, respectively. EcoRI and XhoI restriction sites employed in various protocols for part assembly are also shown. Cleavage of each DNA
with the appropriate enzyme (color-coded arrowheads) generates compatible cohesive ends. These can be connected head-to-tail by ligation
(black arrow) to generate composite parts separated by a 6 nucleotide scar sequence (ggatct). When translated in frame, the scar sequence
between parts encodes glycine-serine, a peptide linker innocuous for most protein fusion applications.
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we lowered the risk of homologous recombination
occurring in the cell by creating three degenerate basic
parts in the BglBrick format, all encoding SH3 ligand
motifs, but each containing a distinct sequence. Combi-
nations of these three degenerate parts were used to
assemble repetitive composite parts by standard assem-
bly. Although we have not observed occurrences of
recombination with devices containing up to four identi-
cal repeats, this can be problematic for assembling
devices with larger numbers of identical repeats (JED
unpublished data).
To show the functionality of our multi-domain fusion
protein devices, each bait was tested for its ability to
form a synthetic complex with prey in an in-vitro GST-
pulldown assay (Figure 3). Baits with and without SH3
peptide ligand motif(s) ran at the expected mobility.
Protein-protein interactions and complex formation
were only observed in the presence of bait containing
SH3 peptide ligand motif(s) and prey containing an SH3
interaction domain. Furthermore, baits containing 4
protein interactions domains were able to pull down
more prey than baits containing a single interaction
domain, indicating as expected, that the amount of prey
pulled down correlates with the number of SH3 peptide
ligand motifs present on the bait. Conversely, no com-
plex formation was observed when bait and prey lacking
protein interaction domains were used in the pull-down.
These data agree well with data obtained for similar
constructs made using a non-BioBricks restriction
enzyme strategy [6]. Furthermore, they demonstrate that
BglBrick parts can be used to create functional multi-
domain fusion protein devices containing repetitive ele-
ments and that the BglBrick scar sequence can be
inserted between expressed protein domains without
significantly affecting function.
Targeted integration of BglBrick devices into the E. coli
genome
Another recurring goal in synthetic biology is to engi-
neer microbial strains that express introduced genes in a
stable and predictable manner, either in single copies or
as part of complex genetic circuits. To achieve this level
of regulation, we need tools that facilitate the targeted
integration of DNA sequences into specific regions of
the bacterial chromosome (for a minireview of site-spe-
cific recombination see [22]). Wanner and coworkers
have described a genomic integration system, based on
CRIM plasmids (for conditional-replication, integration,
and modular), that enables single copy integration of
multiple plasmids into several defined loci of one E. coli
genome [23]. The CRIM plasmids carry an R6K condi-
tional origin of replication, a selectable antibiotic resis-
tance marker, and a phage attachment site (attP). By
supplying a helper plasmid encoding integrase (Int), a
CRIM plasmid can be site-specifically recombined into
its corresponding bacterial attachment site (attB). In the
absence of Int, CRIM plasmids can be maintained extra-
chromosomally provided that the host strain expresses
pir, the gene required for replication of R6K origins.
The CRIM system is a versatile tool because its modu-
larity allows the use of alternative attP and attB sites
(for phages l, HK022, F80, P21, and P22, all of which
target distinct sites of the E. coli genome), various anti-
biotic resistance markers, as well as several polylinkers
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B. Sequence alignment of RBSs
Figure 2 Assembly of lacZ expression devices.( A )S t a n d a r d
assembly of BglBrick basic parts were used to generate a series of
constitutive lacZ expression devices. Each composite part consisted
of a different ribosome binding site part located between promoter
and lacZ coding sequence parts. (B) Sequence alignment of RBS
variants. Asterisks indicate sequence identity. (C) The b-galactosidase
activity of each device (labeled for RBS parts J61140-J61146), along
with a negative control lacking a device (DH10B cells alone), is
shown. For each, the average of 5 individual replicates is shown. A
wide range of activities were observed, indicating the ability to tune
protein expression levels using BglBrick RBS part libraries.
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tions to render the system more robust and compatible
with the BglBrick standard. First, we have facilitated
CRIM plasmid integration by adding the pir gene
needed for replication of R6K origins to the helper plas-
mid. This ensures that CRIM plasmids will be replicated
prior to integration, which, in turn, increases the
chances of a successful integration event. Second, we
have refactored the essential elements of CRIM plasmids
into distinct BglBrick basic parts from which new CRIM
plasmids can be assembled. Finally, we have made mar-
ker-less integration variants of CRIM plasmids, such
that, if desired, antibiotic resistance markers can be
removed from the cell after the integration process is
complete. This is desirable when an application requires
the reuse of an antibiotic resistance marker in the engi-
neered strain, or for high-volume or environmental
release applications where retention of antibiotic resis-
tance is potentially unsafe.
CRIM plasmids contain three essential elements: a
conditional origin of replication, a selectable marker,
and a phage attachment site (attP). Additional elements
in each CRIM plasmid will vary according to its
intended purpose. To make functional CRIM plasmids
v i as t a n d a r da s s e m b l y ,w ef i r st had to construct basic
parts for both the essential and additional elements used
in this application (Figure 4a). For the CRIM elements,
we maintained R6K as the conditional origin of replica-
tion, we used chloramphenicol as the selectable marker,
and opted for the F80 phage attachment site because
the F80 CRIM plasmid was shown to undergo genome
integration most efficiently [23]. Though we highlight
F80 parts here, we also constructed P21 integration
parts (not shown). Additional elements used in this
application include basic parts containing a constitu-
tively active Tet promoter and an RBS described in
other sections of this report; two parts encoding differ-
ent methyltransferases; and one part containing an FRT
recombination site. By flanking sequences with FRT
recombination sites, these can be later targeted for elim-
ination by Flp-mediated recombination [24]. We have
used this tool to remove antibiotic resistance markers
from the E. coli genome following initial integration of
CRIM plasmids.
To functionally test the integration parts, we made
independent strains of E. coli that methylate either BglII
or BamHI restriction sites. Such strains will be useful
for the development of next-generation BglBrick stan-
dard assembly chemistries. First we used BglBrick basic
parts and standard assembly to build CRIM plasmids
carrying methylation devices (Figure 4a). In addition to
the essential CRIM elements, the plasmids contained a
BglII or BamHI methyltransferase expression cassette
composed of a Tet promoter, an RBS, and the
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Figure 3 Assembly of multi-domain fusion protein devices.( A )
Basic parts containing protein-protein interaction ligands were built
using three independent, degenerate sequences encoding an N-
terminal glycine-serine linker and an SH3 interaction peptide.
Composite parts were created by standard assembly of these basic
parts. (B) Experimental design for testing interactions between bait
and prey parts. The number of prey molecules pulled-down by bait
should be dependent on the number of SH3 peptide ligands. (C) A
GST-pulldown experiment was conducted and the proteins
separated via SDS-PAGE and then imaged by Coomassie staining.
No visible interaction was observed when either the bait lacked any
SH3 peptide ligand or the prey lacked an SH3 domain. Bait
containing composite part J62008 with four SH3 peptide ligands,
despite visible proteolytic degradation, was sufficient to pull down
increased amounts of prey compared to bait containing the single
SH3 ligand part J62002.
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Figure 4 Targeted integration of BglBrick parts into the E. coli genome. (A) A variety of basic parts were used to create two
methyltransferase expression devices targeting BamHI and BglII restriction sites (parts J72007 and J72013, respectively). Each device was
recombined into the genome of strain MC1061 by F80 att site integration, resulting in BamHI- and BglII-methylating strains (parts J72015 and
J72014, respectively). (B) Sample experimental design for genomic integration of CRIM plasmids. Circuit components are color-coded and
graphically represented relative to (A) and the top of (B) for easy identification. (1) Host strain MC1061 with unmodified genomic F80 att sites is
transformed with temperature sensitive helper plasmid pInt80-649 (part J2008) and selected on ampicillin plates. (2) Cells are re-transformed with
CRIM plasmid (part J72007), which replicates as a high-copy R6K plasmid employing the pir gene provided by the helper plasmid. (3) The CRIM
plasmid inserts into the genome by recombination with the F80 att site employing the int gene from the helper plasmid. (4) Helper plasmid is
cured by growth at 43°C. (5) Helper plasmid pCP20 encoding Flp recombinase is introduced by transformation and the R6K origin and
chloramphenicol genes are excised from the genome by recombination of FRT sites. (6) Helper plasmid is cured by growth at 43°C, resulting in
the final product containing a genomically-integrated BglBrick part and a single FRT site. (C) Restriction mapping of plasmid J61148-J72011
isolated from BglII- and BamHI- methylating strains (parts J72015 and J72014, respectively) or DH10B (control) confirms the appropriate
protection.
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dard assembly, we flanked the R6K origin and the anti-
biotic resistance marker of each CRIM plasmid with
FRT recombination sites to target them for removal
after genome integration. For the experiment, plasmids
containing methylation devices were introduced into
MC1061 cells previously transformed with a helper plas-
mid carrying pir and the corresponding F80 int gene
(Figure 4b). Following integration into the MC1061 gen-
ome, selection, curing of any remaining extra-chromoso-
mal DNA, and subsequent removal of the R6K and
chloramphenicol resistance gene by Flp-mediated
recombination, we obtained new strains of E. coli that
are capable of methylating BglII and BamHI sites on
plasmids replicating within them. To confirm the pre-
sence and functionality of this genomically-encoded
activity, we transformed each strain with a BglBrick
plasmid (J61148-J72011) that contains a 910-bp BglBrick
part flanked by EcoRI and BglII on the 5’ end, and by
BamHI and XhoI on the 3’ end. Following methylation,
we purified the plasmid and analyzed its methylation
state by restriction enzyme mapping (Figure 4c). As
expected, digestion of control unmethylated DNA with
either BglII and XhoI, or BamHI and EcoRI, liberates
the 910-bp BglBrick part-containing fragment carried in
the test plasmid. In contrast, digestion of the same plas-
mid purified from the BglII or BamHI methylation
strains were protected from BglII or BamHI digestion,
and instead, were only linearized by XhoI or EcoRI. Col-
lectively, these experiments demonstrate that BglBrick
parts are viable tools for the creation of CRIM plasmids
that can be used to specifically target DNAs carrying
functional devices into defined loci of the E. coli
genome.
Discussion
The primary bottleneck in synthetic biology research
today is the construction of physical DNAs, a process
that is often expensive, time consuming, and riddled
with cloning difficulties associated with the uniqueness
of each sequence. A variety of strategies are available to
tackle DNA construction projects. At one end of the
spectrum, there are de novo synthesis techniques to
build DNA sequences starting from single bases, while
at the other end, there are assembly schemes that begin
with physical collections of short DNA sequences and
fuse them head-to-tail to generate larger constructs.
Alongside more traditional restriction enzyme-based
assembly methods, multiple techniques within this spec-
trum are often used in combination. To name a few,
Gene Splicing by Overlap Extension (gene SOEing), is a
sequence-independent, PCR-based method, that enables
site-directed mutagenesis and/or recombination of DNA
sequences without relying on restriction enzyme sites
[25,26]. Sequence and Ligation Independent Cloning
(SLIC) is another PCR-based method that allows the
assembly of multiple DNA fragments in a single reaction
using in-vitro homologous recombination and single-
strand annealing [27]. More recently, there have been
reports of a single-reaction DNA shuffling method
based on type IIs restriction enzymes, known as Golden
Gate Shuffling [28], as well as a single-reaction isother-
mal method for the assembly of multiple overlapping
DNA molecules [29]. Similarly, Tsuge and coworkers
have reported a cloning technique to iteratively con-
struct large sequences of DNA, on the scale of small
g e n o m e s ,a n dt ot r a n s f e rt h e mi n t oh o s tc e l l s[ 3 0 ] .
Despite these and other encouraging advances, every
methodology has unique advantages and flaws, and thus,
there is still no single DNA fabrication protocol that
addresses all assembly needs. For example, even though
prices for de novo gene synthesis continue to drop, in
practice the technique remains prohibitively expensive,
especially for high-throughput applications. As a result,
most synthetic biology labs routinely employ assembly
strategies even when the core elements of their designs
are made using de novo gene synthesis. Similarly, though
assembly reactions are inexpensive in comparison to de
novo gene synthesis, they are complicated by the
uniqueness of each assembly strategy, by errors incurred
during PCR-based methods, and by the need for exten-
sive manual operations, including pipetting, cutting and
pasting reactions, gel purifications, transformations, etc.
As they stand, the existing de novo gene synthesis and
assembly strategies are complementary technologies that
tackle different scales of DNA fabrication.
Strategies for the standard assembly of biological parts
emerge from the recognition that the power of standar-
dized parts lies in their ability to separate function from
assembly, and furthermore, to sustain the development
of a single robust reaction chemistry and protocols sui-
table for all assembly applications. Because each part
has a standardized interface for assembly, each is guar-
anteed to cut in the right place and assemble in the
same way as other parts conforming to the same stan-
dard. In idempotent assembly schemes, such as the Bio-
Bricks™ paradigm, the child of assembling two basic
parts is itself amenable to assembly using the same
assembly reaction. As a result, any number and order of
basic parts can be assembled into larger DNA cassettes
through iterated cycles of identical operations. Thus, the
problem of composition can be pursued without consid-
eration for how the DNAs are assembled. Similarly, the
reliability, cost-effectiveness, throughput, and automa-
tion of assembly reactions can be developed without
consideration of composition. With the increasing com-
plexity of engineered biological systems, there is great
need for robust standard assembly methods that are
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sical entities while minimizing financial and time costs.
The first step in implementing an idempotent stan-
dard assembly strategy requires the definition of techni-
cal standards for parts, such that all parts are amenable
to the same assembly reaction. Here we have described
a new flexible standard for composing biological parts
called BglBricks. In developing the BglBrick standard,
we recognized that the utility of any assembly strategy is
principally based on two factors: first, the intrinsic
robustness of the restriction enzymes involved in the
assembly process; and second, the desirability of the
scar sequence that remains between parts after they
have been joined together. We have addressed these
points by selecting enzymes with an extensive history of
use, demonstrated reliability, high cutting efficiency, and
resulting in an innocuous scar sequence that enables
protein fusion applications in a variety of common host
systems. Consequently, the resulting BglBrick standard
represents an improvement over the original BioBricks™
assembly strategy, whose primary shortcoming is an
inability to support the construction of protein fusions.
Finally, we have showcased use of the BglBrick standard
in 3 diverse applications and demonstrated that it can
be used for most DNA assembly scenarios encountered
in synthetic biology experiments. To date, thousands of
distinct biological parts have been constructed using the
BglBrick standard, and methods for assembly continue
to be actively developed.
Conclusions
The BglBrick standard supports robust reaction chemis-
tries that can be applied for most DNA assembly appli-
cations, including those required for the construction of
multi-domain protein fusions. In so doing, the BglBrick
standard not only separates the laborious problem of
DNA assembly from its functional design, but it also
sets the foundation needed for future automation and
scaling of these processes. Toward this goal we are
developing a variety of approaches, technologies and
reagents that will eventually enable standard assembly of
multi-component genetic systems in vivo using only
automated liquid handling operations. We believe these
tools will provide a foundation from which to transform
and simplify genetic engineering.
Methods
Reagents and strains
DNA-modifying enzymes were purchased from New
England Biolabs.
Oligonucleotides were synthesized by Sigma-Genosys
or IDT and used unpurified. PCR was performed with
the Roche Expand High Fidelity PCR kit. All reactions
were performed according to the manufacturer’s
instructions. DNAs were transformed into bacteria by
heat shock using KCM chemically competent cells.
Unless otherwise noted, all manipulations were per-
formed in E. coli strain DH10B grown at 37°C in LB
liquid medium or agar plates, supplemented with anti-
biotics at 100 μg/mL for ampicillin, and 25 μg/mL for
all others.
Construction of basic parts
Detailed descriptions of the construction of each
BglBrick basic part-encoding plasmid are provided on
individual part pages available at the Registry of Stan-
dard Biological Parts [2] and may be located by their
part number. Using various conventional molecular biol-
ogy techniques, DNA cassettes encoding basic parts
flanked by BglII and BamHI restriction sites at their 5’
and 3’ ends, respectively, were inserted into entry vec-
tor-containing plasmid pBca9145 (part J61148), which
contains a ColE1 origin of replication, an ampicillin
resistance gene, and the BglBrick polylinker. As an
example, the plasmid resulting from introduction of the
J72005 Ptet promoter part into pBca9145 is J61148-
J72005.
Standard assembly of basic parts
Although multiple specific protocols for BglBrick stan-
dard assembly are currently in development, the general
strategy described here can be referred to as suffix inser-
t i o n .B r i e f l y ,t oj o i nt w op l a s m i d sc o n t a i n i n gp a r t sA
and B, in that order, plasmid containing part A is
digested with BamHI (which cuts 3’ of the part) and
XhoI (which cuts the vector). Similarly, plasmid contain-
ing part B is cut with BglII (which cuts 5’ of the part)
and XhoI. DNA fragments are separated by electrophor-
esis, parts of interest are gel purified, ligated, and trans-
formed into E. coli for characterization and
maintenance.
Construction and screening of a ribosome binding site
library
Plasmid pSB1A2-J23100 (part J23100), which encodes
only a constitutive promoter, was used as a template to
PCR amplify a library of RBSs downstream of the pro-
moter by PCR, using oligonucleotides CA998 (5’-GTAT-
CACGAGGCAGAATTTCAG-3’), which targets the
vector backbone, and CA1106R (5’-
CTTGCGGATCCNNCCNNNGTTAGCCAGATC-
TAGCTAGCACTGTACCTAGGACTG-3’), which
includes 5 degenerate bases that target the intended
Shine-Delgarno sequence. PCR products were digested
with EcoRI and BamHI, and ligated into the EcoRI and
BamHI sites of reporter plasmid pBca1101 (part J72009).
Reporter plasmid pBca1101 lacks a promoter driving
expression of a downstream RFP gene, so ligation of the
degenerate PCR products creates devices consisting of a
constitutive promoter, RBS and RFP gene. From the
transformants obtained, 96 individual clones were
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plates using a Tecan Safire 2 fluorescence plate reader.
Several distinct variants, named RBS1-A through RBS1-
G (parts J61140-J61146), that span the range of expres-
sion activities observed within the library were selected
for further characterization and use as basic parts in
standard assembly reactions.
Analysis of lacZ expression devices
Composite lacZ expression devices consisting of a con-
stitutively active Tet promoter (part J72005), one of the
variants identified in the RBS library screen, and a b-
galactosidase coding sequence (part J72010), were gener-
ated via BglBrick standard assembly reactions with vec-
tor pBca9145 (part J61148). For each lacZ expression
variant tested, 5 individual colonies were assayed for b-
galactosidase activity. Cells were grown to saturation in
LB medium supplemented with ampicillin, diluted 1:50
in fresh medium, and then grown to OD600 = 0.5. Activ-
ity was determined according to a modified Miller assay
[31].
Construction of multi-domain fusion protein devices
Composite parts encoding multiple SH3 peptide ligands
were constructed from three, degenerate, single-ligand
basic parts (parts J62002, J62003, and J62004) by stan-
dard assembly reactions. To limit the probability of
recombination due to repetitive sequences, each ligand
basic part was engineered with degenerate codon usage.
Each ligand part also included a degenerate sequence
encoding an N-terminal glycine-serine linker predicted
to be unstructured and flexible that was codon-opti-
mized for expression in E. coli.F r o mt h e s ei n d i v i d u a l
degenerate parts, it was possible to assemble any combi-
nation of SH3 ligands separat e db yf l e x i b l el i n k e r st h a t
include the scar sequence. As an example, part J62008,
which contains four SH3 peptide ligand domains, was
built by joining two composite parts, each with two
ligand domains (parts J62006 and J62007). For this
application, it was necessary to assemble the SH3 pep-
tide ligand cassettes into “bait” expressing devices that
could pull-down “prey” molecules. Theoretically, bait
can be any protein fused to these SH3 ligands, while
prey can be any protein fused to a corresponding SH3
domain. Bait-expressing plasmids were constructed by
digesting HMG-CoA synthase-encoding plasmids
(HMGS) (part J62005) with BglII and XhoI, and ligating
into the T7-driven GST-fusion expression vector pGEX
4T-1 (Pharmacia). The resulting vector was digested
with BamHI and XhoI and used as a backbone for
inserting the BglBrick assembled interaction ligands
digested with BglII and XhoI. Consequently, bait was
expressed as an N-terminal GST-tagged HMGS with a
variable number of SH3 ligands fused to its C-terminus.
Prey was constructed using splicing by overlapping
extension (SOE-PCR) to fuse the SH3 domain to the N-
terminus of HMG-CoA reductase (HMGR). In these
experiments, HMGS and HMGR were used as “carriers”
of the bait SH3 peptide ligand repeat and the prey SH3
domain, and thus, should be considered inert for the
desired binding function.
Fusion protein over-expression, purification, GST pull-
down assays
E. coli strain BLR-DE was used to express all baits and
preys used in these pull-down assays (GST-HMGS-baits
with and without SH3 peptide ligands, and HMGR-
preys with and without SH3 domain). Briefly, cells were
grown overnight at 37°C in 5 mL LB supplemented with
ampicillin. The next morning, cultures were diluted to
an OD600 = 0.05 into 500 mL of LB supplemented with
ampicillin. Cultures were further grown to an OD600 =
0.5-0.7 and subsequently induced with 0.5 mM IPTG
for 5 hours. Cells were isolated by centrifugation, resus-
pended in 35 mL of PBS buffer, and lysed by sonication.
A fast centrifugation step was done to clear the lysate.
The soluble supernatant was split into 1.5 mL aliquots,
flash frozen in liquid nitrogen, and stored at -80°C until
further use. In preparation for the pull-downs, GST-
tagged baits were affinity purified away from cell super-
natants using glutathione agarose beads (Sigma). Briefly,
lysate aliquots were slowly thawed on ice and incubated
with beads pre-washed in PBS buffer at 4°C for 30 min.
They were then isolated by centrifugation using a desk-
top Galaxy minicentrifuge (VWR) for approximately 10
sec., and washed four times with fresh PBS buffer at 4°
C. For the pull-down, the bead-bound, purified bait was
mixed with unpurified, cleared prey lysate and incubated
at 4°C for 30 min. Complexes were isolated by centrifu-
gation as above, and washed four times with fresh PBS
buffer supplemented with 0.05% Tween-20 at 4°C. The
samples were then resolved on 4-12% Bis-Tris NuPAGE
gels (Invitrogen) and visualized by Coomassie stain.
Integration of CRIM plasmids into the E. coli genome
Detailed descriptions of the construction of helper plas-
mids, as well as basic and composite parts used in this
section, are provided on the individual part pages at the
Registry of Standard Biological Parts [2]. After assembly
of full-length CRIM composite parts, such as J72007
(used as example in Figure 4c), the original ColE1 origin
of replication and ampicillin resistance marker from the
initial vector backbone were excised by digestion with
BglII and BamHI. The desired CRIM composite part
was re-circularized by ligation and introduced into E.
coli strain Ec100D::pir116 (Epicentre) for maintenance
as high-copy plasmids on chloramphenicol-supplemen-
ted medium. For genomic integration, the target E. coli
strain MC1061 was first transformed with helper plas-
mid pInt80-649 (part J72008), which contains an ampi-
cillin marker, a temperature-sensitive origin of
replication for maintenance, the int gene for F80 att-
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grown on ampicillin plates under permissive conditions
at 30°C. The resulting cells were made competent again,
re-transformed with CRIM plasmid, and grown on
chloramphenicol plates at 30°C. During this stage,
CRIM plasmids were maintained as high-copy plasmids
by the pir116 g e n ep r o d u c te x p r e s s e df r o mt h eh e l p e r
plasmid. From the transformants obtained, a single col-
ony was grown to saturation in 5 mL LB medium sup-
plemented with chloramphenicol at 37°C, and then re-
streaked on chloramphenicol plates and grown over-
night at 43°C. Following genomic integration of the
CRIM plasmid into the target MC1061 E. coli strain,
growth at this non-permissive temperature cures the cell
of the helper plasmid containing the pir116 gene. From
t h e s ec o l o n i e s ,as i n g l ec o l o n yw a sr e - g r o w nt os a t u r a -
tion in 5 mL LB medium supplemented with chloram-
phenicol at 37°C, and then streaked on ampicillin plates
to confirm loss of the helper plasmid. Genomic DNA
was then isolated from the resulting cells and analyzed
to confirm integration of the CRIM plasmid into the
genome. Specifically, the F80 locus was PCR amplified
with primers CA603F (5’-CTGCTTGTGGTGGTGAAT-
3’) and CA603R (5’-TAAGGCAAGACGATCAGG-3’),
and PCR products were sequenced to confirm the inte-
gration of parts.
Post-integration marker excision from CRIM integrants
Following confirmation of the genomic integration
event, the chloramphenicol marker and R6K origin of
replication originally carried in the CRIM plasmid were
removed from the genome by Flp-mediated recombina-
tion. Briefly, competent cells of the integrant were trans-
formed with helper plasmid pCP20 [23] containing Flp
recombinase, and grown on ampicillin plates under per-
missive conditions at 30°C. Following Flp-mediated
recombination, a single colony was grown to saturation
in 5 mL LB medium lacking antibiotics and then re-
streaked onto LB plates and grown overnight at 43°C to
cure the helper plasmid. From the resulting clones, a
single colony was grown to saturation in LB medium at
37°C, and then re-streaked on ampicillin plates to con-
firm loss of the helper plasmid. Genomic DNA was then
analyzed by PCR and sequencing of the F80 att locus
to confirm loss of the chloramphenicol marker and R6K
origin of replication from the host genome.
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